Testing for Genotoxic Impurities: How Low Should We Go?

Add bookmark

Pharma IQ

Patient safety is a paramount concern for the pharmaceutical industry. Overlooked toxicity liability could not only put patient safety at risk, but also have huge financial implications for a pharmaceutical company. Dr. Fenghe Qiu, Principle Scientist & Leader of the Trace Analysis Group at Boehringer Ingelheim, spoke to Pharma IQ about managing the risk of genotoxic impurity. [inlinead]
To continue reading this story get free access